Fundamentals-based quality & risk · not a recommendation
Nureca Ltd scores 20/100 (Avoid) on the Orion Score — poor business quality (12), poor growth (13) and weak balance-sheet safety (46). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
25/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q3 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q3 2026 | ₹39.64 | ₹3.73 | 6.9% | ₹3.91 |
| Q1 2026 | ₹34.18 | ₹0.81 | -3.2% | ₹0.81 |
| Q4 2025 | ₹31.74 | ₹2.47 | 2.3% | — |
| Q3 2025 | ₹26.46 | ₹-2.8 | -17.2% | ₹-2.80 |
| Q2 2025 | ₹31.19 | ₹-0.48 | -9.6% | ₹-0.48 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹109.66 | ₹0.85 | ₹4.07 | -9.0% |
| FY 2024 | ₹91.93 | ₹-1.79 | ₹0.14 | -13.7% |
| FY 2023 | ₹111.32 | ₹-8.25 | ₹-8.02 | -15.4% |
| FY 2022 | ₹255.55 | ₹44.96 | ₹62.9 | 21.4% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| NURECA ★ | ₹236 Cr | 112.48 | -4.97% | -1.12% | 0.03x | 6.94% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹88,148 Cr | 25.39 | 12.55% | 9.93% | 0.21x | 15.11% |
| ASTERDM | ₹68,390 Cr | 104.34 | 8.93% | 10.07% | 0.46x | 13.98% |
| ABBOTINDIA | ₹59,509 Cr | 38.28 | 36.31% | 34.46% | 0.04x | 27.01% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹209.98 | ₹205.16 | ₹206.58 | ₹219.13 |
| Equity | ₹194.28 | ₹193.11 | ₹194.88 | ₹203.2 |
| Total Debt | ₹4.97 | ₹2.52 | ₹3.33 | ₹4.41 |
| Cash | ₹3.24 | ₹14.06 | ₹0.5 | ₹8.25 |
| Net Debt | — | — | — | — |
| Working Capital | ₹177.55 | ₹183.32 | ₹177.68 | ₹193.96 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 68.13% ↑ | 0% ↓ | 0% ↓ | 31.87% ↓ |
| Q3 FY2026 | 64.97% | 0.08% | 0.04% | 34.91% ↓ |
| Q2 FY2026 | 64.97% ↑ | 0.07% | 0.04% | 34.92% ↓ |
| Q1 FY2026 | 64.33% ↑ | 0.07% ↓ | 0.04% | 35.56% ↑ |
| Q4 FY2025 | 64.3% ↑ | 1.07% ↑ | 0.04% | 34.59% ↓ |
| Q3 FY2025 | 64.06% ↑ | 0.36% ↓ | 0.04% ↑ | 35.54% |
| Q2 FY2025 | 63.78% ↑ | 0.69% ↑ | 0% | 35.53% ↓ |
| Q1 FY2025 | 63.24% | 0.07% | 0% | 36.69% |
No recent corporate actions
Ask: "Is Nureca Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.